SCHEDULE: Versant VI Distributes Monte Rosa Shares to LPs
Schedule 13D Amendment
Versant Venture Capital VI, L.P. distributed 744,800 shares of Monte Rosa Therapeutics common stock to its limited partners without additional consideration.
Summary
- Versant Venture Capital VI, L.P. (Versant VI) effected a pro rata distribution of 744,800 shares of Monte Rosa Therapeutics, Inc. common stock to its limited partners on November 10, 2025.
- This distribution was made without additional consideration.
- Following the distribution, Versant VI beneficially owns 3,334,669 shares, representing 5.1% of Monte Rosa Therapeutics' common stock.
- Versant Vantage I, L.P. continues to beneficially own 1,573,453 shares, representing 2.4% of Monte Rosa Therapeutics' common stock.
- The total outstanding shares of Monte Rosa Therapeutics, Inc. common stock were 65,117,761 as of October 31, 2025, as reported in the Issuer's Form 10-Q.
Sentiment
Score: 5
Explanation: The filing reports a routine pro-rata distribution of shares by a venture capital fund to its limited partners. This is a technical change in beneficial ownership reporting and does not inherently signal positive or negative sentiment towards the underlying company's performance or prospects. It's a neutral event from the perspective of the company's operational health.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Monte Rosa Therapeutics, Inc.'s future operations or financial performance.
Industry Context
This filing reflects a common practice for venture capital funds to distribute shares to their limited partners as an investment matures or as part of their fund's lifecycle management. It does not provide specific insights into broader industry trends for biotechnology or drug development.
Related Party Transactions
- Versant Venture Capital VI, L.P. distributed 744,800 shares of Monte Rosa Therapeutics, Inc. common stock to its limited partners without additional consideration. This is a transaction between the fund and its investors.
Stakeholder Impact
- Shareholders: The distribution results in a slight diffusion of ownership, as shares previously held by Versant VI are now held by its limited partners. This could potentially increase liquidity if LPs decide to sell, but does not immediately impact the company's operations or strategy.
Key Dates
| Date | Description |
|---|---|
| 2021-07-08 | Original Schedule 13D filed by Reporting Persons. |
| 2023-11-09 | Amendment No. 1 to Schedule 13D filed. |
| 2024-08-12 | Amendment No. 2 to Schedule 13D filed. |
| 2024-09-24 | Amendment No. 3 to Schedule 13D filed. |
| 2024-10-30 | Amendment No. 4 to Schedule 13D filed. |
| 2025-10-31 | Date as of which 65,117,761 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-11-06 | Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC. |
| 2025-11-10 | Date Versant VI effected a pro rata distribution of 744,800 shares of Common Stock to its limited partners, requiring this filing. |
| 2025-11-12 | Date of signing of this Amendment No. 5. |
Keywords
Monte Rosa Therapeutics, Versant Venture Capital, Schedule 13D Amendment, Share Distribution, Beneficial Ownership, Biotechnology Investment, Venture Capital Exit
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.